Baseline characteristics of patients with newly diagnosed AML
Characteristic . | Ivosidenib 500 mg, N = 34 . |
---|---|
Age, median (range), y | 76.5 (64-87) |
Age category, n (%), y | |
60 to <75 | 15 (44) |
≥75 | 19 (56) |
Women/men, n | 15/19 |
ECOG PS at baseline, n (%) | |
0 | 8 (24) |
1 | 20 (59) |
2 | 5 (15) |
3 | 1 (3) |
Nature of AML, n (%) | |
De novo | 8 (24) |
Secondary | |
History of MDS | 18 (53) |
History of MPD | 4 (12) |
Treatment-related | 3 (9) |
Other | 1 (3) |
Prior hypomethylating agent, n (%) | 16 (47) |
Cytogenetic risk status by investigator, n (%) | |
Intermediate | 24 (71) |
Poor | 9 (26) |
Unknown | 1 (3) |
Bone marrow blasts, median (range), % | 63 (1-97) |
Hematology, n (%) | |
White blood cells, ×109/L | |
<15 | 28 (82) |
15 to <30 | 4 (12) |
≥30 | 2 (6) |
Hemoglobin, g/L | |
<80 | 5 (15) |
≥80 | 29 (85) |
Platelets, ×109/L | |
<50 | 21 (62) |
≥50 | 13 (38) |
Transfusion dependent, n (%) | |
Red blood cells | 16 (47) |
Platelets | 14 (41) |
Characteristic . | Ivosidenib 500 mg, N = 34 . |
---|---|
Age, median (range), y | 76.5 (64-87) |
Age category, n (%), y | |
60 to <75 | 15 (44) |
≥75 | 19 (56) |
Women/men, n | 15/19 |
ECOG PS at baseline, n (%) | |
0 | 8 (24) |
1 | 20 (59) |
2 | 5 (15) |
3 | 1 (3) |
Nature of AML, n (%) | |
De novo | 8 (24) |
Secondary | |
History of MDS | 18 (53) |
History of MPD | 4 (12) |
Treatment-related | 3 (9) |
Other | 1 (3) |
Prior hypomethylating agent, n (%) | 16 (47) |
Cytogenetic risk status by investigator, n (%) | |
Intermediate | 24 (71) |
Poor | 9 (26) |
Unknown | 1 (3) |
Bone marrow blasts, median (range), % | 63 (1-97) |
Hematology, n (%) | |
White blood cells, ×109/L | |
<15 | 28 (82) |
15 to <30 | 4 (12) |
≥30 | 2 (6) |
Hemoglobin, g/L | |
<80 | 5 (15) |
≥80 | 29 (85) |
Platelets, ×109/L | |
<50 | 21 (62) |
≥50 | 13 (38) |
Transfusion dependent, n (%) | |
Red blood cells | 16 (47) |
Platelets | 14 (41) |
MDS, myelodysplastic syndrome; MPD, myeloproliferative disease.